ISPE Announces Thomas B. Hartman as New CEO and President

Share Article

ISPE announced that Thomas B. Hartman has been appointed as the CEO and President, effective 1 June 2020.

Thomas B. Hartman
It is a true privilege to be given the opportunity to play a significant role in the industry, and I look forward to working with the ISPE Board, staff, worldwide Membership, and all industry stakeholders to further advance and build on ISPE's success over the past 40 years.

The International Society for Pharmaceutical Engineering (ISPE) announced that Thomas B. Hartman has been appointed as the CEO and President, effective 1 June 2020. Tom has a long history of success in the pharmaceutical industry, rising to the role of Vice President of GMP Operations, Biopharm CMC, for GlaxoSmithKline (GSK).

“The recent pandemic highlights the need for effective platforms for collaboration to resolve complex industry challenges,” said Hartman. “ISPE and its more than 18,000 Members are positioned well to support the entire pharmaceutical industry in the development and manufacturing of transformational medicines for patients. It is a true privilege to be given the opportunity to play a significant role in the industry, and I look forward to working with the ISPE Board, staff, worldwide Membership, and all industry stakeholders to further advance and build on ISPE's success over the past 40 years.”

Tom’s extensive executive leadership experience and strong commitment to product quality, includes all aspects of biopharmaceutical CMC supply chain management. Most recently his team established manufacturing capability for the supply of viral vectors, enabling GSK’s cell and gene therapy platform.

He is experienced in all aspects of biopharmaceutical CMC functions including cell banking, materials management, manufacturing including microbial and mammalian expression systems, and support functions including facility monitoring, engineering, capital project management, validation, and quality control, often leading negotiations with international external supply CMO/CRO’s.

Prior to joining GSK in 2001, he held multiple engineering and operations roles with a major US-based chemical manufacturer, including a five-year expatriate role in the Netherlands and the UK, culminating with responsibilities as head of engineering at a large chemical facility. In his career, Tom has successfully conducted business in multiple countries including the US, UK, East/West Europe, China, Korea, Singapore, India, and Mexico.

Tom has been a Member of ISPE since 2001. He has actively participated in the Delaware Valley Chapter and was elected to the ISPE Board of Directors in 2013, most recently serving as the 2019–2020 Vice Chair. He has served on various ISPE committees and was instrumental in starting the ISPE Foundation. Tom holds a degree in Mechanical Engineering from Villanova University and an MBA from Eastern University.

About ISPE
The International Society for Pharmaceutical Engineering (ISPE) is the world’s largest not-for-profit association serving its members through leading scientific, technical, and regulatory advancement across the entire pharmaceutical lifecycle. The 18,500 members of ISPE are building solutions in the development and manufacture of safe, effective pharmaceutical and biologic medicines, and medical delivery devices in more than 90 countries around the world. Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland USA, and its operations center in Tampa, Florida USA. Visit ISPE.org for more information.

For more information, contact:
Amy Henry
Marketing Communications Manager
International Society for Pharmaceutical Engineering (ISPE)
Email: ahenry@ispe.org
ISPE.org

Share article on social media or email:

View article via:

Pdf Print

Contact Author

International Society for Pharmaceutical Engineering (ISPE)
Visit website